Multicenter, Randomized Split-Face Trial of a Crosslinked Hyaluronic Acid Fillers With Lidocaine for Nasolabial Fold Correction
Aesthetic Surgery Journal · 16.06.2026 · 46 (7) · 759-769
DOI: 10.1093/asj/sjaf137 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Aesthetic Surgery Journal, online erschienen am 01.08.2025. Verfasst von Jeanine Downie und 10 weiteren Autor:innen. Hauptthemen laut MEDLINE: Hyaluronic Acid, Dermal Fillers, Nasolabial Fold, Cosmetic Techniques. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Croma Pharma GmbH.
Abstract (Originalsprache)
Background
Nasolabial folds (NLFs) are common age-related facial lines, often treated with dermal fillers. Princess FILLER Lidocaine (PFL; now saypha filler Lidocaine) and Juvéderm Ultra XC (JUXC) are both hyaluronic acid–based fillers used for this purpose.
Objectives
The aim of the authors of this study is to evaluate the effectiveness and safety of PFL in reducing NLF severity compared with JUXC using a split-face study design.
Methods
In this randomized, subject- and investigator-blinded multicenter study, patients with moderate-to-severe NLFs received PFL on one side of the face and JUXC on the other. Baseline NLF severity was assessed using the 5-point NLF-Severity Rating Scale (NLF-SRS). Follow-up assessments occurred at Weeks 12, 24, 36, and/or 48. The primary endpoint was the proportion of NLF-SRS responders at Week 24. Secondary endpoints included assessments by photographic reviewers and treating investigators, along with Global Aesthetic Improvement Scale (GAIS) ratings. Safety was monitored by adverse event reporting and patient diaries. FACE-Q questionnaires evaluated patient satisfaction. Repeat treatment was permitted at Week 36 or 48 if needed.
Results
At Week 24, PFL demonstrated noninferiority to JUXC (82.2% vs 81.9% responders; difference 0.37%, P < .0001). Secondary assessments confirmed this finding. Adverse events occurred in 24.4% of patients post PFL, with most being mild to moderate. Serious treatment-emergent adverse events were rare (1.1%).
Conclusions
PFL is a noninferior alternative to JUXC for treating moderate-to-severe NLFs, with comparable efficacy, safety, and patient satisfaction. Level of Evidence: 1 (Therapeutic) For image description, please refer to the figure legend and surrounding text.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
ORCID-Profile: Jeremy Green, Joel L Cohen
Förderung
- Croma Pharma GmbH
Zitieren
APA
Downie, J., Gold, M., Joseph, J., Green, J., Fabi, S., Bank, D., Cohen, J. L., Shamban, A., Weiss, R., Krames-Juerss, A., & Monheit, G. (2026). Multicenter, Randomized Split-Face Trial of a Crosslinked Hyaluronic Acid Fillers With Lidocaine for Nasolabial Fold Correction. Aesthetic Surgery Journal, 46(7), 759-769. https://doi.org/10.1093/asj/sjaf137
Vancouver
Downie J, Gold M, Joseph J, Green J, Fabi S, Bank D, et al. Multicenter, Randomized Split-Face Trial of a Crosslinked Hyaluronic Acid Fillers With Lidocaine for Nasolabial Fold Correction. Aesthetic Surgery Journal. 2026;46(7):759-769. doi:10.1093/asj/sjaf137
BibTeX
@article{Downie2026,
author = {Downie, Jeanine and Gold, Michael and Joseph, John and Green, Jeremy and Fabi, Sabrina and Bank, David and Cohen, Joel L and Shamban, Ava and Weiss, Robert and Krames-Juerss, Alice and Monheit, Gary},
title = {Multicenter, Randomized Split-Face Trial of a Crosslinked Hyaluronic Acid Fillers With Lidocaine for Nasolabial Fold Correction},
journal = {Aesthetic Surgery Journal},
year = {2026},
volume = {46},
number = {7},
pages = {759--769},
doi = {10.1093/asj/sjaf137}
}
EUVIMED